The effects of N-acetylcysteine on hepatic, hematologic, and renal parameters in cirrhotic patients: a randomized controlled trial
Gastroenterology and Hepatology from Bed to Bench,
Vol. 16 No. 4 (2023),
20 September 2023
https://doi.org/10.22037/ghfbb.v16i4.2443
Abstract
Aim: To evaluate the effects of N-acetylcysteine (NAC) supplementation in cirrhotic patients.
Background: Chronic hepatic inflammation leads to fibrosis and cirrhosis through various mechanisms such as oxidative stress. NAC is one of the intracellular precursors of glutathione that can degrade most reactive oxygen species. Recently, the beneficial effects of NAC in animal and human studies on preventing liver injury progression and improving liver function have been examined. However, more studies on human subjects are still required.
Methods: Well-known cirrhotic patients with a specific etiology and aged 18 to 70 years who referred to the gastrointestinal clinic of Ayatollah Taleghani Hospital from December 2018 to December 2019 were enrolled in the present randomized double-blind controlled trial. Patients in the intervention group received NAC tablets at a dose of 600 mg daily, and the control group received a placebo. Demographic and medical characteristics including whole blood tests, liver and kidney function tests were measured and Child-Pugh and MELD scores calculated for all patients at baseline and after 6 months.
Results: Totally, 60 patients completed the present study (30 patients in the intervention group, and 30 patients in the control group). Hematological and biochemical parameters were normal in both groups with no significant differences at baseline and 6 months after intervention values. Moreover, the renal function indicators including serum creatinine (Cr) and urea (BUN) decreased significantly after intervention. Hepatic parameters also decreased significantly 6 months after intervention. Decreases in the renal and hepatic parameters 6 months after baseline in the control group were not statistically significant.
Conclusion: The results of this study showed that NAC improved hepatic and renal function by decreasing serum urea and creatinine levels but had no significant effect on hematological and biochemical parameters. Furthermore, NAC significantly improved hepatic profiles by decreasing ALT, AST, and ALP in the liver enzymes between the intervention and control groups. Moreover, NAC caused a significant decrease in Child-Pugh and MELD scores.
- N-acetylcysteine
- cirrhosis
- Child-Pugh score
- MELD score
How to Cite
References
Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol 2014;20:2515.
Vendemiale G, Grattagliano I, Caruso ML, Serviddio G, Valentini AM, Pirrelli M, et al. Increased oxidative stress in dimethylnitrosamine-induced liver fibrosis in the rat: effect of N-acetylcysteine and interferon-α. Toxicol Appl Pharmacol 2001;175:130-9.
Hoffer E, Baum Y, Tabak A, Taitelman U. N-acetylcysteine increases the glutathione content and protects rat alveolar type II cells against paraquat-induced cytotoxicity. Toxicol Lett 1996;84:7-12.
Sun T, Liu J, Zhao DW. Efficacy of N-acetylcysteine in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Medicine 2016;95.
Maghsadi Z, Azadmehr A, Moghadamnia AA, Feizi F, Hamidi N. N-Acetylcysteine attenuated pulmonary fibrosis induced by bleomycin via immunomodulation responses. Res Pharm Sci 2023;18:177-184.
Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol 2011;4:391-417.
Tenório MCDS , Graciliano NG , Moura FA , Oliveira ACM, Goulart MOF. N-Acetylcysteine (NAC): impacts on human health. Antioxidants 2021;10:967.
Weiskirchen R. Hepatoprotective and anti-fibrotic agents: it's time to take the next step. Front Pharmacol 2016;6:303.
Rhoden E, Mauri M, Petteffi L, Belló-Klein A, Zettler C, Rhoden C. Protective effect of colchicine on tissue damage caused by free radicals in hepatic cirrhosis: an experimental study in rats. Arq Gastroenterol 1997;34:91-6.
Hu J, Zhang Q, Ren X, Sun Z, Quan Q. Efficacy and safety of acetylcysteine in non-acetaminophen" acute liver failure: A meta-analysis of prospective clinical trials. Clin Res Hepatol Gastroenterol 2015;39:594-9.
Goldberg E, Chopra S. Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis. ©2023 UpToDate, https://www.uptodate.com/contents/cirrhosis-in-adults-etiologies-clinical-manifestations-and-diagnosis. Available in Jan 23, 2023.
Peng Y, Qi X, Guo X. Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Medicine 2016;95:2877.
Tripepi G, Chesnaye NC, Dekker FW, Zoccali C, Jager KJ. Intention to treat and per protocol analysis in clinical trials. Nephrology 2020;25:513-517.
Ntamo Y, Ziqubu K, Chellan N, Nkambule BB, Nyambuya TM, Mazibuko-Mbeje SE, et al. Clinical use of N-acetyl cysteine during liver transplantation: Implications of oxidative stress and inflammation as therapeutic targets. Biomed Pharmacother 2022;147:112638.
Appenrodt B, Lammert F. Renal failure in patients with liver cirrhosis: novel classifications, biomarkers, treatment. Visc Med 2018;34:246-252.
Tumgor G. Cirrhosis and hepatopulmonary syndrome. World J Gastroenterol 2014;20:2586–2594.
Zhang HY, Han DW, Wang XG, Zhao YC, Zhou X, Zhao HZ. Experimental study on the role of endotoxin in the development of hepatopulmonary syndrome. World J Gastroenterol 2005;11:567–572.
Zhang HY, Han DW, Zhao ZF, Liu MS, Wu YJ, Chen XM, Ji C. Multiple pathogenic factor-induced complications of cirrhosis in rats: a new model of hepatopulmonary syndrome with intestinal endotoxemia. World J Gastroenterol 2007;13:3500–3507.
Vercelino R, Tieppo J, Dias AS, Marroni CA, Garcia E, Meurer L, et al. N-acetylcysteine effects on genotoxic and oxidative stress parameters in cirrhotic rats with hepatopulmonary syndrome. Basic Clin Pharmacol Toxicol 2008;102:370-6.
Ibrahim ES, Sharawy A. Effectiveness of intravenous infusion of N-acetylcysteine in cirrhotic patients undergoing major abdominal surgeries. Saudi J Anaesth 2015;9:272–278.
Abdoli N, Sadeghian I, Mousavi K, Azarpira N, Ommati MM, Heidari R. Suppression of cirrhosis-related renal injury by N-acetyl cysteine. Curr Res Pharmacol Drug Discov 2020;1:30-38.
Ommati MM, Amjadinia A, Mousavi K, Azarpira N, Jamshidzadeh A, Heidari R. N-acetyl cysteine treatment mitigates biomarkers of oxidative stress in different tissues of bile duct ligated rats. Stress 2021;24:213-228.
Long LH, Xue CQ, Shi JF, Dong JN, Wang L. Efficacy of hepatoprotective agents with or without antiviral drugs on liver function and fibrosis in patients with hepatitis b: a meta-analysis. Hepat Mon 2015;15:29052.
Kakaei F, Fasihi M, Hashemzadeh S, Zarrintan S, Beheshtirouy S, Asvadi-Kermani T, et al. Effect of N-acetylcysteine on liver and kidney function tests after surgical bypass in obstructive jaundice: a randomized controlled trial. Asian J Surg 2020;43:322-329.
Singh S, Hynan LS, Lee WM; Acute Liver Failure Study Group. Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. Dig Dis Sci 2013;58:1397-402.
Onk D, Özçelik F, Onk OA, Günay M, Ayazoğlu TA, Ünver E. Assessment of renal and hepatic tissue-protective effects of n-acetylcysteine via ammonia metabolism: a prospective randomized study. Med Sci Monit 2018;24:1540-1546.
Ye M, Lin W, Zheng J, Lin S. N-acetylcysteine for chronic kidney disease: a systematic review and meta-analysis. Am J Transl Res 2021;13:2472-2485.
El-Lakkany NM, Seif El-Din SH, Sabra AA, Hammam OA, Ebeid FA. Co-administration of metformin and N-acetylcysteine with dietary control improves the biochemical and histological manifestations in rats with non-alcoholic fatty liver. Res Pharm Sci 2016;11:374-382.
Oliveira CP, Cotrim HP, Stefano JT, Siqueira ACG, Salgado ALA, Parise ER. N-acetylcysteine and/or ursodeoxycholic acid associated with metformin in non-alcoholic steatohepatitis: an open-label multicenter randomized controlled trial. Arq Gastroenterol 2019;56:184-190.
Zafarullah M, Li W, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 2003;60:6-20.
Song W, Liu M, Wu J, Zhai H, Chen Y, Peng Z. Preclinical Pharmacokinetics of Triptolide: A Potential Antitumor Drug. Curr Drug Metab 2019;20:147-154.
Nyui M, Shoji Y, Ueno M, Nakanishi I, Matsumoto KI. Reduction of molecular oxygen by redox active thiols: comparison of glutathione, N-acetylcysteine cysteine, and homocysteine. J Clin Biochem Nutr 2019;65:185-192.
Grisanti S, Cosentini D, Tovazzi V, Bianchi S, Lazzari B, Consoli F, Roca E, Berruti A, Ferrari VD. Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma. Support Care Cancer 2018;26:2929-2935.
Papatheodoridis GV, Cholongitas E, Dimitriadou E, Touloumi G, Sevastianos V, Archimandritis AJ. MELD vs Child-Pugh and creatinine-modified Child-Pugh score for predicting survival in patients with decompensated cirrhosis. World J Gastroenterol 2005;11:3099.
- Abstract Viewed: 134 times
- PDF Downloaded: 213 times